CKPT News and Press, Checkpoint Therapeutics Inc. From 10/18/23

Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous squamous cell carcinoma Biologics License Application review ongoing; PDUFA goal ...

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding (i) Se...

WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a panel prese...

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview...

2023-08-14 17:05:58 ET Checkpoint Therapeutics press release ( NASDAQ: CKPT ): Q2 GAAP EPS of -$1.05. As of June 30, 2023, Checkpoint’s cash and cash equivalents totaled $7.4 million, compared to $4.8 million at March 31, 2023 and $12.1 million at December 31, 2022,...

Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results demonstrate substantial increases in complete response rates and continued favorable safety prof...

Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus pla...

2023-08-01 19:01:20 ET Summary A PDUFA date of January 3, 2024 has been established by which FDA will decide upon by then whether or not cosibelimab should be approved for the treatment of cSCC. It is said that the cutaneous squamous cell carcinoma market in the U.S. alone could r...

2023-07-31 13:08:57 ET Gainers: Mallinckrodt ( MNK ) +42% . Fifth Wall Acquisition Corp. III ( FWAC ) +40% . Tupperware Brands Corporation ( TUP ) +40% . GoodRx Holdings ( GDRX ) +37% . Archer Aviation ( ACHR ) +36% . Steakho...

2023-07-31 08:46:52 ET Checkpoint Therapeutics ( NASDAQ: CKPT ) has entered into a definitive agreement for the issuance and sale of an aggregate of ~3.24M shares of its common stock, ~3.24M of Series A and B warrants to purchase up to 3.2M shares, at a purchase price of $3.09...